Hydroxypyridine-thione Zinc Binding for Metallo-beta-lactamase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current β-lactamase inhibitors are inadequate against metallo β-lactamases, particularly the VIM2 carbapenemase, which contributes to β-lactam drug resistance, and existing compounds like L-captopril have limitations due to metabolic oxidation and non-specific zinc binding, necessitating the development of novel zinc binding group (ZBG) alternatives.
Innovation Solution
Substituted 1-hydroxypyridine-2(1H)-thiones, such as those with a 6-substituted carboxylic acid group, are used in combination with antibacterial agents to inhibit metallo β-lactamases by forming specific interactions with zinc ions, enhancing inhibition potency and selectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If L-captopril is used to inhibit metallo β-lactamases, then inhibitory activity is achieved, but non-specific zinc binding and metabolic oxidation occur
Solution Approach 1:
The patent changes the chemical parameters of the zinc binding group by replacing the thiol group in L-captopril with a hydroxamate group. This parameter change maintains the ability to bind zinc ions and inhibit metallo β-lactamases while eliminating the harmful effects of non-specific zinc binding and metabolic oxidation that plague the thiol-containing compounds.
Solution Approach 2:
The patent modifies the local chemical quality at the zinc binding site by substituting the thiol group with a hydroxamate group. This local modification preserves the essential zinc-binding function while removing the problematic properties of the original thiol group, achieving selective and stable inhibition.
2Reliability
If existing β-lactamase inhibitors are used, then some inhibition is achieved, but they are inadequate against metallo β-lactamases
Solution Approach 1:
The patent applies parameter changes by developing compounds with hydroxamate groups that are specifically optimized for metallo β-lactamase inhibition. This chemical parameter modification enables the inhibitors to effectively target the zinc ions in metallo β-lactamases, a class of enzymes that traditional inhibitors cannot adequately inhibit.
3Power
If compounds with thiol groups are used for zinc binding, then inhibition potency is achieved, but metabolic oxidation and non-specific binding occur
Solution Approach 1:
The patent changes the chemical parameter of the zinc binding group from thiol to hydroxamate. This substitution maintains the high inhibition potency by preserving strong zinc-binding capability while dramatically improving metabolic stability and binding specificity, as the hydroxamate group is resistant to metabolic oxidation and provides more selective zinc coordination.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of substituted 1-hydroxypyridine-2(1H)-thiones with antibacterial agents demonstrates nanomolar inhibition of VIM2 and other metallo β-lactamases, restoring the efficacy of β-lactam antibiotics against drug-resistant bacteria while minimizing toxicity to other zinc enzymes.
Implementation Method 1
forming specific interactions with zinc ions
Implementation Method 2
replaces the thiol as the zinc binding group (ZBG)
Implementation Method 3
a salt bridge interaction between its carboxylate to the ionized Arg205
Implementation Method 4
forms a five-membered complex via their oxygen and sulfur atoms with zinc
Data Source
AI summary
Combinations comprising substituted 1-hydroxypyridine-2(1H)-thiones or a pharmaceutically acceptable salt thereof and an antibacterial agent are disclosed. Also disclosed are therapeutic methods comprising the administration of a substituted 1-hydroxypyridine-2(1H)-thione or a pharmaceutically acceptable salt thereof and an antibacterial agent.